Products - Autoimmune - Neurology - Autoimmune encephalitis

Autoimmune encephalitis

Contact our Autoimmune Product Team for further details and information

Information

Autoimmune encephalopathies exhibit autoantibodies against neuronal cell surface antigens. The antibodies are directed against glutamate receptors (type NMDA or type AMPA), GABAB receptors, DPPX, voltage-gated potassium channels (VGKC) or VGKC-associated proteins (LGI1, CASPR2, TAG-1/ contactin-2). Since these antigens play a direct or indirect role in synaptic signal transduction, the associated autoimmunities manifest with seizures and neuropsychiatric symptoms. The resulting conditions include special forms of autoimmune limbic encephalitis, neuromyotonia or Morvan’s syndrome. These severe, potentially lethal, syndromes can have a non-paraneoplastic or paraneoplastic etiology.

Diagnostic Guidelines

The diagnosis of autoimmune encephalitides is generally based on a combination of the characteristic clinical picture, supporting findings from brain MRT, EEG and CSF analysis if necessary, and antibody determination in serum/CSF. Monospecific recombinant assays are the method of choice for serological diagnostics and can be combined with conventional immunohistochemical detection procedures. The following conditions must be excluded by differential diagnostics: infectious encephalitides (especially HSV), other autoimmune etiologies (e.g. limbic encephalitis with autoantibodies against Hu, Ma2, CV2, amphiphysin) and clinically similar diseases of the central and/or peripheral nervous system. A diagnostic discrimination from atypical encephalitides should also be taken into consideration. It should be considered that overlap syndromes and combinations of different syndromes can also occur. When a positive serological result is obtained, a comprehensive tumor investigation should be undertaken.

The frequency of underlying tumors ranges from 10 to 70%, depending on the type of antibody. The antibodies most likely play a causal role in the pathogenesis. Since appropriate therapy (immunomodulatory intervention, tumor resection) results in considerable regression of symptoms in most patients, early diagnosis is important for a favorable prognosis.

Autoimmune encephalitis products

For Research Use Only. Not For Use In Diagnostic Procedures.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.

wdt_ID Method Parameter Substrate Species/ Antigen
649 IFA antibodies against glutamate receptor (type NMDA)
650 IFA Autoimmune Encephalitis Mosaic 1
glutamate receptor (type NMDA)
glutamate receptor (type AMPA1)
glutamate receptor (type AMPA2)
contactin-associated protein 2 (CASPR2)
leucine-rich glioma-inactivated protein 1 (LGI1)
GABA B receptor
6 BIOCHIPs per field:
transfected cells
transfected cells
transfected cells
transfected cells
transfected cells
transfected cells
EU 90
EU 90
EU 90
EU 90
EU 90
EU 90
651 IFA RC-IFA Neurology Mosaic 14A
glutamate receptor (type NMDA)
contactin-associated protein 2 (CASPR2)
IgLON family member 5 (IgLON5)
dipeptidyl aminopeptidase-like protein 6 (DPPX)
leucine-rich glioma-inactivated protein 1 (LGI1)
6 BIOCHIPs per field:
transfected cells
transfected cells
transfected cells
transfected cells
transfected cells
transfected cells
EU 90
EU 90
EU 90
EU 90
EU 90
EU 90
652 IFA glutamate receptor (type NMDA) transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
653 IFA glutamate receptor (type NMDA) EUROPattern transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
655 IFA Autoimmune Encephalitis Mosaic 6 EUROPattern
glutamate receptor (type NMDA)
contactin-associated protein 2 (CASPR2)
glutamate receptors (type AMPA1/2)
leucine-rich glioma-inactivated protein 1 (LGI1)
6 BIOCHIPs per field:
transfected cells
transfected cells
transfected cells
transfected cells
transfected cells
transfected cells
EU 90
EU 90
EU 90
EU 90
EU 90
EU 90
658 IFA Autoimmune Encephalitis Mosaic 6 glutamate receptor (type NMDA) contactin-associated protein 2 (CASPR2) glutamate receptors (type AMPA1/2) leucine-rich glioma-inactivated protein 1 (LGI1) dipeptidyl aminopeptidase-like protein 6 (DPPX) GABA B receptor 6 BIOCHIPs per field:
transfected cells
transfected cells
transfected cells
transfected cells
transfected cells
transfected cells
EU 90
EU 90
EU 90
EU 90
EU 90
EU 90
666 IFA Autoimmune Encephalitis Mosaic 6 glutamate receptor (type NMDA) contactin-associated protein 2 (CASPR2) glutamate receptors (type AMPA1/2) leucine-rich glioma-inactivated protein 1 (LGI1) dipeptidyl aminopeptidase-like protein 6 (DPPX) GABA B receptor 6 BIOCHIPs per field: transfected cells transfected cells transfected cells transfected cells transfected cells transfected cells EU 90 EU 90 EU 90 EU 90 EU 90 EU 90
667 IFA glutamate receptor (type AMPA1)
glutamate receptor (type AMPA2)
glutamate receptor (type AMPA2)
transfected cells
transfected cells
control transfection
(3 BIOCHIPs per field)
EU 90
EU 90
EU 90
668 IFA antibodies against GABA B receptor
669 IFA GABA B receptor transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
670 IFA GABA B receptor EUROPattern transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
671 IFA antibodies against dipeptidyl aminopeptidase-like protein 6
(DPPX ab control)
672 IFA dipeptidyl aminopeptidase-like protein 6
(DPPX)
transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
673 IFA dipeptidyl aminopeptidase-like protein 6
(DPPX) EUROPattern
transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
674 IFA antibodies against IgLON family member 5 (IgLON5)
675 IFA IgLON family member 5 (IgLON5) transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
676 IFA Anti-VGKC-Ass. Proteins Mosaic 1 EUROPattern
leucine-rich glioma-inact. prot. 1 (LGI1)
contactin-associated protein 2 (CASPR2)
3 BIOCHIPs per field:
transfected cells
transfected cells
control transfection
EU 90
EU 90
EU 90
677 IFA Anti-VGKC-Ass. Proteins Mosaic 1
leucine-rich glioma-inact. prot. 1 (LGI1)
contactin-associated protein 2 (CASPR2)
3 BIOCHIPs per field:
transfected cells
transfected cells
control transfection
EU 90
EU 90
EU 90
678 IFA antibodies against leucine-rich glioma-inactivated protein 1
(LGI1 ab control)
679 IFA antibodies against contactin-associated protein 2
(CASPR2 ab control)
680 IFA contactin-associated protein 2 (CASPR2) transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
681 IFA leucine-rich glioma-inactivated protein 1 (LGI1) transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
Method Parameter Substrate Species/ Antigen
Contact our Autoimmune Product Team for further details and information
Download Our Latest <br/>EUROIMMUN US Product Catalog

Product Catalog

Download Our Latest
EUROIMMUN US Product Catalog

Download The EUROIMMUN US Product Catalog (PDF 12MB)

2024 EUROIMMUN US

Privacy Policy | Sitemap